robatumumab robatumumab robatumumab (proposed inn; also known as sch 717454 and mk-7454) is a monoclonal antibody and an antineoplastic by merck and schering-plough. it binds to cd221, the insulin-like growth factor 1 receptor. robatumumabmonoclonal antibodytypewhole antibodysourcehumantargetcd221clinical dataatc codenoneidentifierscas number934235-44-6 nchemspidernoneuniiv983921h3bkeggd10056 nchemical and physical dataformulac6418h9960n1732o1992s42molar mass144602.93 g·mol−1 ny (what is this?) (verify) phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and ewing's sarcoma are complete. merck has since discontinued development.